News Conference News ACC 2024 Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6 Yael L. Maxwell April 08, 2024
News Conference News ACC 2022 Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years Michael O'Riordan April 04, 2022
News Conference News ACC 2019 My Takeaways From ACC 2019: Breaking With Embargoes? Despite the Drama, Embargoes Set to Stay Shelley Wood April 05, 2019
News Conference News ACC 2019 Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery Michael O'Riordan March 17, 2019
News Conference News ACC 2017 Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery Michael O'Riordan March 19, 2017
News Opinion Editor's Corner ACC 2016 Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016 Shelley Wood April 13, 2016
News Conference News ACC 2016 Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients L.A. McKeown April 04, 2016
News Conference News ACC 2016 Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial Yael L. Maxwell April 03, 2016
News Conference News ACC 2015 Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR Yael L. Maxwell March 15, 2015
News Conference News ACC 2014 ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation Yael L. Maxwell April 03, 2014
News Conference News ACC 2014 CHOICE Trial, TVT Registry Shed Light on Evolving TAVR Outcomes, Risks L.A. McKeown March 31, 2014
News Conference News ACC 2012 PARTNER: TAVR Remains as Effective as Surgery at 2 Years March 26, 2012